H. Lundbeck Past Earnings Performance
Past criteria checks 3/6
H. Lundbeck has been growing earnings at an average annual rate of 7%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 4.3% per year. H. Lundbeck's return on equity is 11.3%, and it has net margins of 12.5%.
Key information
7.0%
Earnings growth rate
7.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 4.3% |
| Return on equity | 11.3% |
| Net Margin | 12.5% |
| Next Earnings Update | 05 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How H. Lundbeck makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 21,441 | 2,687 | 9,320 | 4,361 |
| 30 Jun 24 | 20,671 | 2,586 | 9,173 | 3,654 |
| 31 Mar 24 | 20,239 | 2,298 | 9,041 | 3,549 |
| 31 Dec 23 | 19,912 | 2,290 | 8,706 | 3,457 |
| 30 Sep 23 | 19,614 | 2,467 | 8,426 | 3,386 |
| 30 Jun 23 | 19,381 | 2,479 | 8,115 | 3,471 |
| 31 Mar 23 | 18,918 | 2,384 | 8,082 | 3,617 |
| 31 Dec 22 | 18,246 | 1,916 | 7,689 | 3,754 |
| 30 Sep 22 | 17,619 | 1,603 | 7,398 | 3,846 |
| 30 Jun 22 | 16,913 | 1,236 | 7,127 | 3,947 |
| 31 Mar 22 | 16,398 | 1,109 | 6,768 | 3,884 |
| 31 Dec 21 | 16,299 | 1,318 | 6,625 | 3,820 |
| 30 Sep 21 | 16,521 | 1,873 | 6,698 | 3,711 |
| 30 Jun 21 | 16,971 | 1,965 | 6,680 | 3,655 |
| 31 Mar 21 | 17,381 | 2,110 | 6,720 | 2,999 |
| 31 Dec 20 | 17,672 | 1,581 | 6,912 | 3,753 |
| 30 Sep 20 | 17,818 | 904 | 6,812 | 3,760 |
| 30 Jun 20 | 17,490 | 1,242 | 6,744 | 3,538 |
| 31 Mar 20 | 17,366 | 1,507 | 6,672 | 4,039 |
| 31 Dec 19 | 17,036 | 2,313 | 6,413 | 3,116 |
| 30 Sep 19 | 16,811 | 3,091 | 6,212 | 3,214 |
| 30 Jun 19 | 17,309 | 3,395 | 6,143 | 3,302 |
| 31 Mar 19 | 17,766 | 3,606 | 6,061 | 3,313 |
| 31 Dec 18 | 18,117 | 3,907 | 6,039 | 3,277 |
| 30 Sep 18 | 18,313 | 3,806 | 6,120 | 3,069 |
| 30 Jun 18 | 18,028 | 3,627 | 6,174 | 2,903 |
| 31 Mar 18 | 17,608 | 3,236 | 6,298 | 2,765 |
| 31 Dec 17 | 17,234 | 2,624 | 6,482 | 2,705 |
| 30 Sep 17 | 17,007 | 2,544 | 6,428 | 2,769 |
| 30 Jun 17 | 16,607 | 1,988 | 6,462 | 2,839 |
| 31 Mar 17 | 16,075 | 1,612 | 6,424 | 2,887 |
| 31 Dec 16 | 15,634 | 1,211 | 6,293 | 2,967 |
| 30 Sep 16 | 15,202 | 290 | 6,475 | -1,979 |
| 30 Jun 16 | 14,923 | -1,289 | 7,320 | 3,196 |
| 31 Mar 16 | 14,801 | -5,427 | 7,573 | 3,095 |
| 31 Dec 15 | 14,594 | -5,694 | 7,762 | 3,097 |
| 30 Sep 15 | 14,108 | -5,879 | 7,814 | 8,003 |
| 30 Jun 15 | 13,625 | -4,615 | 6,928 | 2,666 |
| 31 Mar 15 | 13,444 | -565 | 6,581 | 2,790 |
| 31 Dec 14 | 13,468 | -153 | 6,298 | 2,689 |
| 30 Sep 14 | 13,808 | 503 | 6,208 | 2,670 |
| 30 Jun 14 | 14,181 | 765 | 6,147 | 2,782 |
| 31 Mar 14 | 14,269 | 119 | 6,814 | 2,807 |
| 31 Dec 13 | 15,258 | 855 | 6,749 | 2,834 |
Quality Earnings: LDBB has high quality earnings.
Growing Profit Margin: LDBB's current net profit margins (12.5%) are lower than last year (12.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LDBB's earnings have grown by 7% per year over the past 5 years.
Accelerating Growth: LDBB's earnings growth over the past year (8.9%) exceeds its 5-year average (7% per year).
Earnings vs Industry: LDBB earnings growth over the past year (8.9%) did not outperform the Pharmaceuticals industry 28.7%.
Return on Equity
High ROE: LDBB's Return on Equity (11.3%) is considered low.